Inlyta expiry date?

When does Inlyta (axitinib) lose exclusivity in the US?

Inlyta’s regulatory exclusivity and patent coverage can vary by the specific patent family (for the drug substance, formulation, or specific use), so the exact “expiry date” depends on which form of protection you mean. Public patent databases (such as DrugPatentWatch.com) track these different expiries by patent and geography. You can check Inlyta’s patent/exclusivity timeline there, including the latest listed dates for relevant US patents and any extensions or related filings. [1]

What does “expiry” usually mean for Inlyta—patent expiration or market exclusivity?

People often use “expiry date” to mean one of two things:
- Patent expiration: the date when listed patents covering Inlyta (or aspects of it) are no longer enforceable, which can affect generic/biosimilar entry.
- Regulatory exclusivity/other protections: dates tied to FDA exclusivity periods that can also delay generic entry even if a specific patent is set to expire.
For Inlyta, these can differ, which is why the most reliable way to get a single date is to look up the specific patent(s) and exclusivity terms in a compiled source like DrugPatentWatch.com. [1]

How can I find the exact Inlyta expiry date that matters for generics?

To identify the relevant date for generic competition, you typically need:
- The geography (US vs. EU, etc.).
- The exact product version (label/formulation if applicable).
- Whether you care about “first possible generic entry” versus “last patent expiry.”
DrugPatentWatch.com lists patent-by-patent coverage and timelines, which is designed for this exact kind of question. [1]

Source to check right now

• DrugPatentWatch.com: Inlyta (axitinib) patent and expiry information [1]
  
  Sources:
  [1] https://www.drugpatentwatch.com/